Cargando…
Role of biologics in severe eosinophilic asthma – focus on reslizumab
Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain si...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936812/ https://www.ncbi.nlm.nih.gov/pubmed/27445482 http://dx.doi.org/10.2147/TCRM.S111862 |
_version_ | 1782441617180852224 |
---|---|
author | Pelaia, Girolamo Vatrella, Alessandro Busceti, Maria Teresa Gallelli, Luca Preianò, Mariaimmacolata Lombardo, Nicola Terracciano, Rosa Maselli, Rosario |
author_facet | Pelaia, Girolamo Vatrella, Alessandro Busceti, Maria Teresa Gallelli, Luca Preianò, Mariaimmacolata Lombardo, Nicola Terracciano, Rosa Maselli, Rosario |
author_sort | Pelaia, Girolamo |
collection | PubMed |
description | Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain significant therapeutic benefits by additional biologic treatments targeting interleukin-5 (IL-5), given the key pathogenic role played by this cytokine in maturation, activation, proliferation, and survival of eosinophils. In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids. These important therapeutic effects of reslizumab, demonstrated by several controlled clinical trials, have led to the recent approval by US Food and Drug Administration of its use, together with other antiasthma medications, for the maintenance treatment of patients suffering from severe uncontrolled asthma. |
format | Online Article Text |
id | pubmed-4936812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49368122016-07-21 Role of biologics in severe eosinophilic asthma – focus on reslizumab Pelaia, Girolamo Vatrella, Alessandro Busceti, Maria Teresa Gallelli, Luca Preianò, Mariaimmacolata Lombardo, Nicola Terracciano, Rosa Maselli, Rosario Ther Clin Risk Manag Review Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain significant therapeutic benefits by additional biologic treatments targeting interleukin-5 (IL-5), given the key pathogenic role played by this cytokine in maturation, activation, proliferation, and survival of eosinophils. In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids. These important therapeutic effects of reslizumab, demonstrated by several controlled clinical trials, have led to the recent approval by US Food and Drug Administration of its use, together with other antiasthma medications, for the maintenance treatment of patients suffering from severe uncontrolled asthma. Dove Medical Press 2016-07-01 /pmc/articles/PMC4936812/ /pubmed/27445482 http://dx.doi.org/10.2147/TCRM.S111862 Text en © 2016 Pelaia et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Pelaia, Girolamo Vatrella, Alessandro Busceti, Maria Teresa Gallelli, Luca Preianò, Mariaimmacolata Lombardo, Nicola Terracciano, Rosa Maselli, Rosario Role of biologics in severe eosinophilic asthma – focus on reslizumab |
title | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
title_full | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
title_fullStr | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
title_full_unstemmed | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
title_short | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
title_sort | role of biologics in severe eosinophilic asthma – focus on reslizumab |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936812/ https://www.ncbi.nlm.nih.gov/pubmed/27445482 http://dx.doi.org/10.2147/TCRM.S111862 |
work_keys_str_mv | AT pelaiagirolamo roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab AT vatrellaalessandro roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab AT buscetimariateresa roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab AT gallelliluca roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab AT preianomariaimmacolata roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab AT lombardonicola roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab AT terraccianorosa roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab AT masellirosario roleofbiologicsinsevereeosinophilicasthmafocusonreslizumab |